COVAXIN shows interim efficacy of 81% in phase 3 clinical trials: Bharat Biotech
News | March 03, 2021 18:30 ISTIndia's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.